Investors & Media

Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen

– Study met its primary endpoint, achieving statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C) compared to placebo at all doses tested – Key secondary endpoints were met including statistically significant reductions in triglycerides and angiopoietin-like-3

Read more
You are now leaving to visit